Genprex to Present at Upcoming June Investor Conferences

On June 2, 2022 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported the Company’s participation in the following upcoming investor and industry conferences to be held in June 2022 (Press release, Genprex, JUN 2, 2022, View Source [SID1234615486]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: LD Micro Invitational

Virtual Presentation Date: Available on-demand within the virtual platform for all delegates beginning June 8 at 4:00 p.m. PT

Presenter: Ryan Confer, Genprex’s Chief Financial Officer

A recording of this presentation will be available for replay on Genprex’s website for a period of time.

Event: BIO International Convention

Aptose Presents Highlights from Corporate Update and KOL Event

On June 2, 2022 Aptose Biosciences, Inc. (NASDAQ: APTO, TSX: APS), reported that in the section of updated clinical findings with HM43239, the fifth bullet point should read "Eight total responses, including seven CRs and one PR, and favorable safety achieved at three separate dose levels (80 mg, 120 mg, 160 mg)" (Press release, Aptose Biosciences, JUN 2, 2022, View Source [SID1234615524]). The corrected release follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today released highlights from a key opinion leader (KOL) and corporate update event held today, June 2, 2022. The event included an up-to-date review of clinical data for Aptose’s two investigational products under development for hematologic malignancies: HM43239, an oral, myeloid kinome inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, dual lymphoid and myeloid kinome inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory B-cell malignancies, and in a separate Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).

Guest KOLs included Brian Druker, M.D., of the Oregon Health & Science University, Naval G. Daver, M.D., of The University of Texas MD Anderson Cancer Center, and Brian Andrew Jonas, M.D., Ph.D., of the University of California, Davis, Comprehensive Cancer Center, who discussed the current treatment landscape and unmet medical need in treating patients with acute myeloid leukemia (AML), as well as their experiences with Aptose’s investigational therapies.

The webcast of the presentation, including the Q&A with the guest KOLs, is available on Aptose’s website here.

Aptose provided updated clinical findings with HM43239, a potent suppressor of FLT3, SYK, JAK 1/2 and mutant forms of cKIT kinases operative in AML:

Clinically validated in a highly diverse set of relapsed/refractory (R/R) AML patients
Fast Track Designation supported by multiple complete remissions (CRs) in FLT3-mutant refractory R/R AML, including those who failed prior therapy with other FLT3 inhibitors
New CRi at 160 mg dose in a R/R AML patient with wildtype FLT3 and other adverse mutations
Patient with CRi at 120 mg dose bridged to hematopoietic stem cell transplantation
Eight total responses, including seven CRs and one PR, and favorable safety achieved at three separate dose levels (80 mg, 120 mg, 160 mg)
One DLT of muscle weakness (not rhabdomyolysis) reported at 200 mg
Three separate doses (80 mg, 120 mg, 160 mg) selected for Expansion Clinical Trials
Single agent Expansion Clinical Trials in FLT3-mutated and FLT3-unmutated AML expected to begin in the second half of 2022
Combination (HM43239 with venetoclax) Expansion Clinical Trials in FLT3-mutated and FLT3-unmutated AML expected to begin in the first half of 2023
Aptose also reviewed clinical findings with the new G3 formulation of luxeptinib (Lux):

G3 formulation was designed to increase plasma exposure and lower pill burden
Patients already administered G3 formulation at 50 mg, 100 mg and 200 mg
G3 formulation is being tested in patients with R/R B-cell malignancies and R/R AML
G3 formulation encouraging with rapid absorption and exposures maintained over 3 days
Plan transition from G1 to G3 continuous dosing if PK modeling studies are supportive
"We’re pleased to announce a new complete remission (CRi) today with HM43239 in a relapsed AML patient with wildtype FLT3 and mutations in diverse genes (RAS, BCOR, U2AF1, SETBP1), expanding the genotypes and R/R AML patient population that may respond to this drug that has thus far been generally well tolerated," said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer. "We’ve identified three doses and target patient populations for our next stage of Expansion Clinical Trials with HM43239, as we move along a pathway toward registrational studies. For Lux, our new G3 formulation appears to be significantly better absorbed than the original formulation and we continue to believe in its potential as a unique dual lymphoid and myeloid kinome inhibitor."

Prothena to Participate in Jefferies Healthcare Conference

On June 2, 2022 Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, reported that members of its senior management team will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday June 8, 2022 at 8:30 AM ET (Press release, Prothena, JUN 2, 2022, View Source [SID1234615523]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat can be accessed through the investor relations section of the Company’s website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for at least 90 days following the presentation date.

Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology

On June 2, 2022 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, reported that it has expanded its existing collaboration with Advanced BioMatrix, a division of BICO Group AB (STO: BICO), for Lineage’s HyStem cell/drug delivery technology (Press release, Lineage Cell Therapeutics, JUN 2, 2022, View Source [SID1234615499]). Under the expanded collaboration, Advanced BioMatrix will broaden its current focus of manufacturing and supplying R&D-grade HyStem to the research community to include the development, supply and/or licensing of clinical/commercial GMP- (Good Manufacturing Practice) grade material for its customers. The amended agreement increases the milestone payments and royalty percentages due to Lineage upon ABM reaching certain development milestones and/or product sales.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to broaden the scope of our agreement with Advanced BioMatrix and the opportunity to include the commercial supply of clinical-grade HyStem as part of ABM’s biomaterials & bioprinting portfolio which is widely available to the cell therapy product development community," stated Brian M. Culley, Lineage CEO. "We have decided this year to place a greater emphasis on business development and licensing and we believe the decision to broaden our partnership with ABM is an example of our ability to rapidly monetize prior investments in our technology platform and its related intellectual property. Alongside our prioritized assets, other assets which are not core to our cell transplant platform can create new opportunities for cash flow and support our development pipeline. Our strategy is to identify and pursue opportunities to unlock value from our business and to utilize capital from these corporate alliances to advance our novel cell therapy programs."

"The mission of Advanced BioMatrix is to enable the future of life-saving treatments, and the HyStem technology can now be more fully utilized as a tool towards accomplishing this mission," added Bowman Bagley, Advanced BioMatrix CEO.

HyStem is a patented hydrogel which mimics naturally occurring extracellular matrix, the structural network of molecules surrounding cells in organs and tissues and essential to cellular function and tissue structure. HyStem biomaterial has been shown to support cellular attachment and survival as well as compatibility with a wide variety of cells and tissue types including brain, bone, skin, cartilage, vascular and heart tissues.

Sihuan and CTTQ-Akeso Team up to Test AXL Inhibitor and PD-1 in Solid Tumors

On June 2, 2022 Sihuan Pharma and CTTQ-Akeso (Shanghai) Biomed reported that it will cooperate to test Sihuan’s AXL inhibitor paired with CTTQ-Akeso’s anti-PD-1 in patients with solid tumors (Press release, Sihuan Pharmaceutical, JUN 2, 2022, View Source [SID1234615498]). Xuanzhu Biopharm, the novel drug subsidiary of Sihuan, has already been approved to start China trials of its AXL inhibitor in advanced solid tumors and hematological malignancies. CTTQ-Akeso was approved to launch its PD-1 (penpulimab), a product co-developed by Sino Bio and Akeso, as a third-line therapy for Hodgkin’s lymphoma. The companies plan to test the combination in patients with non-small cell lung cancer

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!